SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 ...

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations Four programmed death ligand 1 (PD-L1) immunohistochemistry assays (28-8, 22C3, SP263, and SP142) have been approved ...

Hematogenix, an industry leader in the field of integrated pathology services for drug development and clinical testing, announces the availability of the FDA approved PD-L1 companion diagnostic ...

CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, announced the availability of a PD-L1 (programmed death-ligand 1) immunohistochemical (IHC) protein ...

Nearly 20 million people could be vaccinated against coronavirus disease 2019 in December; FDA approves a companion diagnostic for triple-negative breast cancer (TNBC); Anthony Fauci, MD, urges ...